Latest News-CSTONE PHARMACEUTICALS Mediaroom_Page

CStone announces China's NMPA has accepted its new drug application for sugemalimab in the treatment of stage III NSCLC

* Sugemalimab becomes the world's first anti-PD-1/PD-L1 monoclonal antibody to significantly impr...

2021-09-02 08:05 3380

CStone Pharmaceuticals Announces 2021 Interim Results

SUZHOU, China, Aug. 26, 2021 /PRNewswire/ -- CStone Pharmaceuticals (CStone, HKEX: 2616), a leading...

2021-08-26 19:14 5057

CStone Pharmaceuticals Selected as a Constituent of HSCI

SUZHOU, China, Aug. 20, 2021 /PRNewswire/ -- CStone Pharmaceuticals (HKEX: 2616, "CStone" or the "C...

2021-08-20 20:24 5734

CStone announces positive registrational study of the first-in-class drug ivosidenib in Chinese patients with relapsed or refractory acute myeloid leukemia, and NDA has been accepted by the China NMPA and considered for Priority Review

* Ivosidenib (TIBSOVO®, the brand name in the U.S.) is the first isocitrate dehydrogenase 1 (IDH1...

2021-08-03 08:05 3528

CStone announces updated results for AYVAKIT(R) (avapritinib) in Chinese patients with advanced GIST at ESMO World Congress on Gastrointestinal Cancer 2021

* AYVAKIT has demonstrated significant anti-tumor activity in Chinese patients with PDGFRA D842V ...

2021-07-08 08:05 3451

CStone announces China NMPA acceptance of IND application for CS2006/NM21-1480, a PD-L1/4-1BB/HSA multi-specific antibody-based molecule, marking further expansion of its Pipeline 2.0 strategy

SUZHOU, China, July 7, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leadin...

2021-07-07 08:05 2852

CStone announces positive registrational study of GAVRETO® (pralsetinib) in Chinese patients with RET-mutant medullary thyroid cancer

* Key efficacy data for GAVRETO showed deep and durable anti-tumor activity in Chinese patients w...

2021-06-28 08:05 4978

CStone announces positive GAVRETO® (pralsetinib) registrational study data for first-line treatment of advanced RET fusion-positive non-small cell lung cancer and plans to submit a new indication application

* Key efficacy data showed that GAVRETO demonstrated deep and durable clinical activity in Chines...

2021-06-24 08:05 6110

CStone announces first prescriptions of precision therapy GAVRETO® (pralsetinib) issued across China for the treatment of adults with locally advanced or metastatic RET fusion-positive non-small cell lung cancer after platinum-based chemotherapy

SUZHOU, China, June 21, 2021 /PRNewswire/ -- GAVRETO® (pralsetinib), a precision therapy discovered...

2021-06-21 13:06 3006

CStone Announces the First-in-Class Registrational Clinical Trial of Sugemalimab Met its Primary Endpoint in Stage III NSCLC and Plans to Submit a New Drug Application

* Sugemalimab becomes the world's first anti-PD-1/PD-L1 monoclonal antibody to successfully impro...

2021-05-28 08:10 7802

CStone Announces Acceptance of New Drug Application in Hong Kong for Avapritinib for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumor

SUZHOU, China, May 12, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leadin...

2021-05-12 14:09 3377

CStone Announces NMPA Acceptance of New Drug Application of Selective Inhibitor GAVRETO(R) (Pralsetinib) with Priority Review Designation for the Treatment of Advanced or Metastatic RET-Altered Thyroid Cancer Patients

SUZHOU, China, April 26, 2021 /PRNewswire/ -- CStone Pharmaceuticals (CStone, HKEX: 2616), a leadin...

2021-04-26 21:14 3690

CStone Announces China NMPA New Drug Approval of Precision Therapy AYVAKIT® (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor

SUZHOU, China, March 31, 2021 /PRNewswire/ -- CStone Pharmaceuticals (CStone, HKEX: 2616), a leadin...

2021-03-31 18:20 6633

CStone Pharmaceuticals Reports Financial Results and Business Highlights for Full-year 2020

SUZHOU, China, March 25, 2021 /PRNewswire/ -- CStone Pharmaceuticals (CStone, HKEX: 2616), a leadin...

2021-03-25 22:03 4303

CStone Announces New Drug Approval of GAVRETO(R) (pralsetinib) as First Selective RET Inhibitor in China, Providing a New Therapy for a Subset of Non-Small Cell Lung Cancer Patients

* GAVRETO has been approved for the treatment of adults with locally advanced or metastatic RET f...

2021-03-24 10:46 5105

CStone Pharmaceuticals Reports Efficacy and Safety Data from the ARROW Trial of Pralsetinib in Chinese Patients with Advanced RET Fusion-positive Non-Small Cell Lung Cancer after Platinum-based Chemotherapy at IASLC WCLC 2020

SUZHOU, China, Jan. 28, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEx: 2616), a leadi...

2021-01-28 10:15 4496

CStone's Partner Blueprint Medicines Announces U.S. FDA Approval of GAVRETO (pralsetinib) for the Treatment of Patients with Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancer

SUZHOU, China, Dec. 10, 2020 /PRNewswire/ -- The partner of CStone Pharmaceuticals ("CStone", HKEX:...

2020-12-10 08:30 4106

ESMO ASIA Congress 2020 | CStone Pharmaceuticals announces the results of GEMSTONE-302, Sugemalimab has the potential to provide a new treatment option for patients with advanced NSCLC

SUZHOU, China, Nov. 23, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leadi...

2020-11-23 09:30 3750

CStone Pharmaceuticals Announces China's NMPA has Accepted its New Drug Application for anti-PD-L1 Monoclonal Antibody Sugemalimab in First-Line Advanced NSCLC

* Currently, there is no anti-PD-L1 monoclonal antibody approved for stage IV NSCLC inChina * A...

2020-11-12 10:58 4758

CStone and LegoChem Biosciences Enter Global Licensing Agreement for New Antibody Drug Conjugate

* CStone to acquire exclusive rights for development and commercialization outsideSouth Korea for...

2020-10-29 07:15 3744